The global radiopharmaceuticals market was valued at USD 6.6 Bn in 2024 and is projected to reach USD 14.6 Bn by the end of 2035, expanding at a CAGR of 7.6% from 2025 to 2035. Growth is driven by the rising prevalence of cancer and cardiovascular diseases, increasing adoption of nuclear medicine in diagnostic imaging, and ongoing advancements in targeted radiotherapy.

The radiopharmaceutical business is witnessing a high growth rate due to technological developments in nuclear medicine and increasing applications in targeted therapy and diagnostic imaging. Radiopharmaceuticals have been referred to as labeled medicine with radioisotopes employed for disease diagnosis or treatment, that is, oncology, cardiology, and neurology.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

Key Findings of the Market Report

• Diagnostic Radiopharmaceuticals currently dominate the market share (~73%–82%), with Technetium-99m remaining the "workhorse" isotope for SPECT imaging due to its ideal half-life and established global supply chain.
• Therapeutic Radiopharmaceuticals are the fastest-growing segment (~20% CAGR). Breakthroughs in treating prostate cancer (PSMA-targeting) and neuroendocrine tumors have validated RLTs as a multi-billion dollar pillar of oncology.
• Oncology is the leading application, accounting for over 53% of revenue in 2026. However, Neurology is emerging as a high-growth area due to the rising use of Amyloid and Tau PET tracers for early Alzheimer’s diagnosis.
• North America leads the market with a ~44%–49% share, driven by a dense network of cyclotrons and high R&D spending.
• Asia-Pacific is the fastest-growing region (~11% CAGR), fueled by the rapid expansion of nuclear medicine infrastructure in China and India.

Global Radiopharmaceuticals: Growth Drivers

• The Rise of Theranostics: 2026 marks the widespread clinical adoption of the "theranostic pair" concept. By using a diagnostic tracer (e.g., Gallium-68) to identify patients who will respond to a specific therapeutic isotope (e.g., Lutetium-177), clinicians are achieving unprecedented precision in cancer care.
• Supply Chain Localization: To combat the "short half-life" bottleneck, 2026 has seen a surge in decentralized production. Companies are investing in regional "hub-and-spoke" radiopharmacy networks to ensure doses reach patients within strict 4–12 hour windows.
• Alpha-Emitter Breakthroughs: While Beta-emitters (like Lu-177) are current leaders, Alpha-emitters (Actinium-225, Lead-212) are the 2026 innovation focus. These isotopes deliver higher energy over shorter distances, effectively "shredding" cancer cell DNA while sparing healthy surrounding tissue.
• AI-Enhanced Dosimetry: AI is now standard for personalized dose planning, allowing radiologists to calculate the exact amount of radiation absorbed by a tumor versus healthy organs, significantly reducing off-target toxicity.

Global Radiopharmaceuticals: Regional Landscape

• North America: The global innovation hub. Growth is driven by the rapid commercialization of new tracers and favorable reimbursement for PET/CT procedures.
• Europe: Heavily focused on regulatory harmonization and centralized isotope production. Germany and Belgium remain critical global suppliers of raw radioisotopes.
• Asia-Pacific: The expansion engine. China is rapidly building out its domestic cyclotron capacity to reduce reliance on imported isotopes, while India is seeing a surge in specialized cancer hospitals offering RLT.

Global Radiopharmaceuticals: Key Players

The market is consolidating as "Big Pharma" (Novartis, Eli Lilly, AstraZeneca) acquires specialized radiotech firms to secure pipelines and manufacturing slots.

• Novartis AG (Market leader in RLT with Pluvicto and Lutathera)
• GE HealthCare (Leader in PET/SPECT imaging equipment and diagnostic tracers)
• Bayer AG (Pioneer in Alpha-therapies with Xofigo)
• Curium SAS (Global leader in isotope manufacturing and distribution)
• Cardinal Health, Inc. (The world's largest radiopharmacy network)
• Lantheus Holdings, Inc. (Leader in PSMA-targeting diagnostic agents)
• Telix Pharmaceuticals (Rapidly growing leader in "Illuccix" imaging kits)
• Eli Lilly (Point Biopharma) (New heavyweight in the RLT space)
• ITM Isotope Technologies Munich SE
• Jubilant Pharmova Limited

Recent Developments (2025–2026)

• February 2026: Novartis announced a major expansion of its automated radioligand manufacturing facility in Indianapolis, aiming to triple global supply of Lu-177 therapies.
• January 2026: Eli Lilly (via Point Biopharma) released Phase III data for its next-gen PNT2002 therapy, positioned to challenge the current standard of care in metastatic prostate cancer.
• Late 2025: AstraZeneca entered the market with a USD 2.4 billion acquisition of Fusion Pharmaceuticals, signaling a strategic move into Actinium-based Alpha-therapies.

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=213&ltype=S

Global Radiopharmaceuticals: Segmentation

By Type

• Diagnostic Radiopharmaceuticals (SPECT, PET) — (Market Leader)
• Therapeutic Radiopharmaceuticals (RLT, Alpha-emitters) — (Fastest Growth)

By Radioisotope

• Technetium-99m (Workhorse of SPECT)
• Fluorine-18 (Cornerstone of PET)
• Lutetium-177 (Therapeutic Leader)
• Gallium-68 (Theranostic Growth Leader)

By Application

• Oncology (Dominant Share; ~53%)
• Cardiology (Myocardial Perfusion Imaging)
• Neurology (Alzheimer’s & Parkinson’s)

By End-User

• Hospitals & Clinics (Current Leader; ~68%)
• Specialized Diagnostic Centers

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com     
Email: sales@transparencymarketresearch.com